semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bone Metastasis Aged 18 or older Radiographic or histologic proof of metastatic bone disease Histologic diagnosis of the primary tumour or if the diagnosis is unknown at least adequate diagnostic investigations into the origin of the metastasis (e.g. dissemination imaging, histology, biopsy) Bone metastasis deriving from the bones of the extremities  Primary bone tumours (benign and/or malignant) No informed consent signed Communication with patient is hampered (e.g. language barrier, severe cognitive impairment, dementia)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastasis to Bone Aged 18 or older Bone metastasis deriving from the following bones humerus, ulna, radius femur, tibia, fibula Radiographic or histologic proof of metastatic bone disease Histologic diagnosis of the primary tumour or if the diagnosis is unknown at least adequate diagnostic investigations into the origin of the metastasis (e.g. dissemination imaging, histology, biopsy) Receive surgical treatment with palliative intent for a pathologic fracture or impending pathologic fracture  Primary bone tumours (benign and/or malignant) No informed consent signed Communication with patient is hampered (e.g. language barrier, severe cognitive impairment, dementia) Lesions in the small bones of the extremities (Surgical) treatment with curative intent
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Histologically/cytologically confirmed diagnosis of breast cancer. Radiological evidence of inoperable locally advanced or metastatic breast cancer HER2 negative breast cancer (based on the most recent analyzed biopsy) defined as a negative in situ hybridization test or an immunohistochemistry status of 0, 1+ or 2+ Received at least 2 and no more than 5 prio chemotherapeutic regimens in locally advanced and/or metastatic setting Prior therapy has to an anthracycline and a taxane in any combination or order For Expansion part: Triple-negative breast cancer defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0,1+ or 2+ER abnd PR status <10% by local laboratory testing  Previous systemic treatment with PI3K,mTOR or AKT inhibitors (allowed in the escalation part) Previous treatment with eribulin (allowed in the escalation part). Known hypersensitivity to any of the excipients of PQR309 or eribulin.Concurrent treatment with other approved or investigational antineoplastic agent Symptomatic Central Nervous System metastases. The patient must have completed any prior local treatment for CNS metastases > 28 days prior to first dose of the study drug (including radiotherapy and/or surgery) Clinically manifested diabetes mellitus(treated and/or clinical signs with fasting glucose >125mg/dl or HbA1c>7%), or documented steroid induced diabetes mellitus
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer The patients signed the written informed consent The patients present with non-metastatic unilateral invasive ER-positive, HER2-negative breast cancer with a primary breast tumor > 2cm by imaging or an axillary lymph node > 2cm by imaging Postmenopausal women with age less than 70 years old The patients have no history of hormone therapy, chemotherapy, breast cancer surgery and radiotherapy The patients have normal cardiac functions by echocardiography The patients' ECOG scores are ≤2 The patients can swallow pills The results of patients' blood tests are as follows Hb≥90g/L WBC≥4E+9/L  The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus The patients have active infections that were not suitable for chemotherapy The patients have severe non-cancerous diseases The patients have bilateral breast cancers or multifocal breast cancers or inflammatory breast cancers The patients have a history of previous treatment with mTOR inhibitors The patients are undergoing current administration of anti-cancer therapies, or are attending other clinical trials The patients are in some special conditions that they cannot understand the written informed consent, such as they are demented or hawkish The patients have allergic history or contraindication of any of the interventional drugs
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Carcinoma Documentation of Disease: 1.1 Subjects must have histologically confirmed invasive breast cancer and registration must occur within 14 months after the first histologic diagnosis of invasive breast cancer A core biopsy interpreted as invasive cancer meets this criterion; if no core biopsy is performed, the date of first histologic diagnosis will be the date of first surgical procedure that identifies invasive cancer (biopsy, lumpectomy or mastectomy) Neoadjuvant subjects should have no evidence of clinical T4 disease prior to chemotherapy and surgery; for neoadjuvant patients can be defined by either clinical stage prior to therapy or pathologic stage at surgery; if patient is eligible based on either, they are eligible for the study Bilateral breast carcinoma is allowed provided diagnoses are synchronous that is, within 3 months of one another and at least one of the two breast carcinomas meet the and neither Her-2 positive or inflammatory No evidence of metastatic disease 1.2 Her-2 negative, defined as In-situ hybridization (ISH) ratio of < 2.0 (if performed) Immunohistochemistry (IHC) staining of 0-2+ (if performed) Deemed to not be a candidate for Her-2 directed therapy. 1.3 Eligible tumor-node-metastasis (TNM) Stages
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer Eligible patients will any patients with biopsy-proven breast cancer and biopsy-proven axillary lymph node metastases at Beth Israel Deaconess Medical Center who are candidates for Neoadjuvant Chemotherapy or Neoadjuvant Endocrine therapy A core needle biopsy or fine needle aspiration is acceptable for diagnosis of metastatic disease in lymph nodes Patients will be identified as possible participants in the Radiology Imaging suites and Breast Surgery Clinics  -Patients with inflammatory breast cancer or distant metastases will be excluded from participating in this study
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Invasive Breast Cancer • histologically confirmed primary invasive breast cancer by core needle biopsy  • pathological diagnosed ductal carcinoma in situ or microinvasive breast cancer by core needle biopsy patient plans to receive neo-adjuvant system therapy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Metastatic Breast Cancer Stage IV Breast Cancer Female patients with histologically verified metastatic breast cancer (stage IV) with measurable metastases, between 18 and 80 years of age, who had undergone at least three lines of chemotherapy and had an expected survival time of at least 3 months  Patients fulfilling at least one of the following will be excluded from participation in the study Abnormal liver function classified as total bilirubin >34 μmol/L or ALAT > 3 times of the upper limit of normal (ULN). In case of metastases in the liver, the ALAT limit for is set to 5хULN Abnormal kidney function defined by serum creatinine >120 μmol/L Abnormal coagulation capacity defined by the relative arbitrary concentration of coagulation factors 2,7,10; INR >1.5 Verified metastases to the brain Synchronous cancer except for non-melanoma skin cancer and early stage of cervical cancer Abnormal hematology status defined by hemoglobin < 9.0 g/dL, platelet count < 100,000/mm^3 or leucocytes < 3 x 10^9/L Clinically significant abnormal ECG Karnofsky performance status score <60% Pregnant or breast feeding women
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women age 18 years or older Confirmed histologic diagnosis of invasive adenocarcinoma of the breast, including MSKCC pathology confirmation ER, PR and HER2 testing in progress (i.e. on outside or MSKCC biopsy report) HER2-positive pathology is permitted Operable tumor measuring ≥1.5 cm in maximal diameter Any nodal status Multifocal and multicentric disease is permitted Synchronous bilateral invasive breast cancer is permitted The tumor should be more than 5 mm from the skin No indication of distant metastases  Inflammatory breast cancer Medical history and concurrent diseases Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results Prohibited Treatments and/or Therapies Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses). However, use of corticosteroids is allowed for the treatment of immune related Adverse Events (irAEs), or adrenal insufficiency Any non-oncology vaccine therapy used for prevention of infectious diseases within 4 weeks prior to first dose of ipilimumab Prior treatment with a CD137 agonist, ipilimumab or other CTLA4 inhibitor Prior investigational agents within 2 weeks prior to first dose of ipilimumab Prior therapy with any anti-cancer agents including chemotherapy, adjuvant chemotherapy, immunosuppressive agents, surgery or radiotherapy within 2 weeks prior to first dose of ipilimumab
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female patient with breast cancer 2. Age > 18 years old 3. Available primary breast tumor sample with adjacent normal epithelial structures 4. Informed consent obtained and signed  Primary tumor size < 1cm 2. Surgical tumor sample without available adjacent normal epithelial structures
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Cancer of Breast Breast Carcinoma Newly diagnosed clinical stage II or III ER+/HER2+ breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal, staging is to be based on AJCC 7 Tumor size at least 2 cm in one dimension by clinical or radiographic exam (World Health Organization (WHO) criteria). Patients with histologically confirmed palpable lymph nodes may be enrolled regardless of breast tumor size. A palpable mass is not required as long as the mass is at least 2 cm in one dimension by radiographic exam At least 18 years of age Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Normal bone marrow and organ function as defined below Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcl Platelets ≥ 100,000/mcl Total bilirubin ≤ institutional upper limit of normal (IULN) AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN  Prior systemic therapy for indexed breast cancer Indeterminate or negative HER2 status Inflammatory breast cancer A history of other malignancy ≤ 5 years from diagnosis of indexed BC with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix Currently receiving any other investigational agents or received any within the past 28 days Know to be HIV positive Known hepatitis B or C infection A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, letrozole, trastuzumab, any other aromatase inhibitor, any other monoclonal antibody, or other agents used in the study Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e., grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Breast Cancer Patient scheduled to undergo lumpectomy for breast cancer at BIDMC Core needle biopsy revealing invasive breast cancer or DCIS Female Minimum age of 21 years Eligible for breast conserving surgery, lumpectomy and radiation Estrogen receptor positive (ER+) on core needle biopsy, or if estrogen receptor negative (ER-), have evaluable estrogen receptor status with positive internal control on core biopsy Progesterone receptor positive (PR+) on core needle biopsy if biopsy indicates invasive cancer, or if progesterone receptor negative (PR-) on biopsy indicating invasive cancer, have evaluable progesterone receptor status with positive internal control on core biopsy HER2 IHC and/or FISH ordered on core biopsy, if biopsy indicates invasive cancer Oncotype DX or other genetic assay performed on core biopsy or not requested Ability to understand and the willingness to sign a written informed consent document  Contraindicated for radiation therapy Pregnancy. (Pregnant women will be excluded from this study because radiation therapy is contraindicated during pregnancy.) Current invasive cancer or DCIS at the site of a previous surgery Any systemic neoadjuvant (or preoperative) therapy between the core biopsy and lumpectomy Involvement in another therapeutic trial for breast cancer at Dana Farber or elsewhere Risk of poor cosmetic outcome after initial lumpectomy and possible additional excision, as assessed by a study surgeon Recommendation for mastectomy based on radiology Patients that have complex DCIS as indicated on radiology, which would require excising a large tissue volume No or equivocal ER, PR or HER2 testing performed prior to surgery if biopsy indicates invasive cancer No or equivocal ER testing performed prior to surgery if biopsy indicates ductal carcinoma in situ
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the study treatment regimen and follow-up, must be obtained and documented according to the local regulatory requirements Adult women greater than 18 years old Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2 breast cancer Cyclin D1 positive as defined as a total immunohistochemical score of 5 or greater Hormone receptor positive as defined as ≥ 10% positive stained cells HER2-normal (IHC score 0-1 or FISH negative [in-situ hybridization (ISH) ratio <= 2.0 status]) Tumor size at least 5 mm with planned primary surgery at Mount Sinai A negative urine dipstick pregnancy test  Estrogen receptor negative invasive breast carcinoma as defined as less than 10% stained cells Prior antiestrogen therapy Tumor size less than 5 mm Prior diagnosis of thrombosis or known hypercoagulable state Known history of bleeding diathesis Known liver disease Prior treatment with neoadjuvant therapy Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema) Current severe or uncontrolled systemic disease Pregnancy or lactation period. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices) during study treatment